Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio.

Development 246

Development Drugs Clinical Development Licensing 246

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany. The companies will select a varied group of skilled researchers for the project.

Development 246

Development Drugs In-Vivo Engineer 246

Worldwide Clinical Trials

DECEMBER 7, 2023

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. What Differentiates Mid-Size CROs?

Clinical Development 341

Clinical Development Clinical Trials Clinical Trials Trials 341

XTalks

JUNE 4, 2024

In the ever-evolving landscape of pharmaceutical development, the complexity of early phase clinical trials is increasing. This surge in complexity is driven by escalating drug development costs, heightened competition and advanced scientific innovations. And that has a lot of downstream consequences.” This trend, which Dr.

Clinical Development 110

Clinical Development Development Clinical Trials Clinical Trials 110

Pharmaceutical Technology

FEBRUARY 20, 2023

While there is no cure to this neurodegenerative condition, academics and companies are pushing through with research that could help patients and their families. Different approaches that are studied include antisense oligonucleotides (ASOs), and gene therapies, which are in early clinical trials.

Development 246

Development Gene Therapy Protein Gene 246

XTalks

MAY 28, 2024

VivoSense , a pioneering company in the field of digital health technologies (DHTs) and digital endpoints for clinical trials, is aiming to enhance the efficiency and efficacy of clinical research. This approach can speed up development and improve data quality, potentially leading to more effective and personalized therapies.

Clinical Development 116

Clinical Development Development Clinical Trials Clinical Trials 116

Pharma Mirror

FEBRUARY 25, 2022

This joint service offering, DRIVE™-Biologics, will leverage Abzena’s strength in design and developability, and cell line development through to commercial manufacturing.

Clinical Development 130

Clinical Development Development Manufacturing Medicine 130

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 3, 2023

Researchers at the Indian Institute of Science (IISc) have found that picolinic acid, a natural compound produced by mammalian cells, can block several disease-causing viruses such as SARS-CoV-2 and influenza A viruses. The Institute is now looking for partners in pharma companies to pursue further clinical development of the findings.

Pharma Companies 159

Pharma Companies Research Clinical Development Development 159

Camargo

DECEMBER 20, 2021

One of the biopharmaceutical industry’s most closely watched forthcoming regulatory developments is the FDA’s imminent reauthorization of the Prescription Drug User Fee Act (PDUFA). A key provision of PDUFA VII is a budget and staffing increase for the Center for Biologics Evaluation and Research (CBER). Beefing Up CBER.

Gene Therapy 184

Gene Therapy Gene Development Production 184

Pharmaceutical Technology

SEPTEMBER 8, 2024

Sonidegib phosphate is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Non-Small Cell Lung Cancer.

Research 130

Research Clinical Development Development 130

Pharmaceutical Technology

MARCH 30, 2023

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research and the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) have launched the Lupus Research Alliance (LRA) in a bid to advance research for the condition. Asian, Hispanic, and Native American women are also at higher risk.

Development 162

Development Drugs FDA Approval Clinical Development 162

Pharmaceutical Technology

JUNE 12, 2023

Accordingly, the development of non-opioid painkillers is experiencing a surge in activity and despite numerous novel targets receiving high levels of attention, cannabinoids have emerged as strong favourites to replace opioid-related medications. On 9 May, National Fentanyl Awareness Day was observed in recognition of the US opioid crisis.

Drugs 358

Drugs Development Clinical Development Sales 358

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Camargo

JULY 30, 2021

Barry Mangum talks the importance of pediatric research, its evolution over the years, and the obstacles and opportunities that the industry faces as it moves forward. How long have you been in pediatric clinical research, and how did you enter the field? We used drugs we developed in adults off-label in children.

Clinical Research 226

Clinical Research Research Gene Therapy Drugs 226

Pharmaceutical Technology

MAY 12, 2023

Angelini Pharma has entered an exclusive global development and commercialisation deal with JCR Pharmaceuticals to develop and commercialise new biologic therapies to treat epilepsy. The company will receive reimbursement of research expenses and an upfront payment, and will also be eligible for $505.5m

Development 130

Development Clinical Development Research 130

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Pharmaceutical Technology

MARCH 20, 2023

Predictive Oncology and Cancer Research Horizons, a part of Cancer Research UK (CRUK), has collaborated to drive cancer drug development using the former’s PEDAL platform. This helps in more informed drug-tumour type combinations selection for clinical development.

Research 130

Research Drugs Development Clinical Development 130

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. Astellas could pay Cullgen up to $85m upon using its license option regarding the deal.

Protein 130

Protein Development Licensing Licensing 130

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The post Ono Pharmaceutical enters research deal with Monash University appeared first on Pharmaceutical Technology.

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

OCTOBER 18, 2022

Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.

Antibody 130

Antibody Development Sales Clinical Trials 130

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 16, 2024

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, has announced a strategic alliance to accelerate access to oncology clinical (..)

Clinical Trials 147

Clinical Trials Clinical Trials Trials Clinical Research 147

Pharmaceutical Technology

OCTOBER 28, 2022

2seventy bio has announced a strategic collaboration with JW Therapeutics to expedite the research and development of T cell-based immunotherapies. This programme is currently being developed under a partnership with Regeneron. It is intended to develop T cell receptor (TCR) therapies for treating MAGE-A4 positive solid tumours.

Development 130

Development Gene Therapy Production Clinical Trials 130

Outsourcing Pharma

AUGUST 3, 2021

The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.

Research 130

Research Scientist Clinical Research Medicine 130

pharmaphorum

AUGUST 16, 2021

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. The post Beckley Psytech raises $80m for psychedelic meds development appeared first on.

Development 135

Development Medicine Clinical Development Research 135

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

FEBRUARY 21, 2023

Japanese firm Teijin has announced its basic agreement on a capital and business alliance with Axcelead to establish a drug discovery research joint venture (JV) company. In addition to supporting drug discovery research, the new company will investigate and acquire candidate compounds for new drugs.

Research 130

Research Drugs Clinical Development Development 130

Pharmaceutical Technology

APRIL 17, 2024

Ftortiazinon is under clinical development by Gamaleya Federal Research Center of Epidemiology and Microbiology and currently in Phase II for Urinary Tract Infections.

Research 100

Research Clinical Development Development 100

FDA Law Blog

NOVEMBER 10, 2024

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.

Production 69

Production Clinical Development Development Regulation 69

Pharmaceutical Technology

MAY 22, 2023

“As the world’s first humanised IgG4-κ monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the company.

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. . Topic sponsors are not involved in the creation of editorial content.

Development 130

Development Gene Therapy Genetics Gene 130

Pharmaceutical Technology

DECEMBER 1, 2022

The latest development is based on the findings from the clinical programme including the double-blind, randomised, placebo-controlled Phase III PUNCH CD3 trial. Ferring Pharmaceuticals president Per Falk said: “This is the first FDA approval of a live biotherapeutic and the culmination of decades of research and clinical development.

FDA Approval 264

FDA Approval Trials Clinical Development Development 264

Pharmaceutical Technology

DECEMBER 7, 2022

Pfizer has entered a research partnership and exclusive licence agreement with Clear Creek Bio to progress new SARS-CoV-2 papain-like protease (PLpro) inhibitors’ discovery and development for the oral treatment of Covid-19. On entering the clinic, Pfizer will solely handle the development and marketing works of the candidate.

Development 130

Development Clinical Trials Clinical Trials Clinical Development 130

Pharmaceutical Technology

JANUARY 4, 2024

TBO-309 is under clinical development by Heart Research Institute and currently in Phase II for Acute Ischemic Stroke.

Research 100

Research Clinical Development Development 100